Market Potential for MDX Alcobra Investor Breakfast July 15, 2014
|
|
- Rachel Powers
- 5 years ago
- Views:
Transcription
1 Market Potential for MDX Alcobra Investor Breakfast July 15, 2014
2 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately, potential or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the translation of interest in using MDX into actual sales, MDX drawing patients from existing therapies, any forecast information provided herein, including market size, pricing, penetration rates and others and the future unmet need in the ADHD space. In addition, historic results of scientific research do not guarantee that the conclusions of future research would not suggest different conclusions or that historic results referred to in this press release would be interpreted differently in light of additional research. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the Risk Factors section of the annual report on Forma 20-F for the year ended December 31, 2013 filed with the Securities and Exchange Commission on March 28, Any forward-looking statement that we make in this presentation speaks only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation. 2
3 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 3
4 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 4
5 TRxs (millions) ADHD Market Growth 70 US ADHD Market TRxs (millions) % Annual Growth 9.3% 12.4% 10.4% 4.5% 6.2% 2013 Total ADHD Sales = $8.3 billion Source: IMS, NPA, TRxs 6 5
6 Adult ADHD is Now Half the Market and Growing Faster than Pediatric Adult vs. Pediatric Total Market TRxs (millions) % 46% 47% 56% 54% 53% TRx % Growth vs. Prior Year Pediatric 1.2% 3.4% Adult 9.0% 9.7% Total Market 4.5% 6.2% Pediatric Adult Source: IMS, NPA, TRxs, by Age 7 6
7 High Rxing MDs estimate that about Half of Adult ADHD Patients they see are Predominately Inattentive Subtype Estimate of Adult ADHD Patient Subtypes (Percent of Patients) 35% Predominately Inattentive 52% Predominately Hyperactive-impulsive 13% Combined Hyperactive-impulsive and Inattentive n=127 S7. Of the adult ADHD patients you see in a typical month, what percent have each of the following subtypes? 7
8 Time to Peak Share in the ADHD Market has been Fairly Rapid Product US Approval Date Year of Peak TRx Share Years to Peak Share Peak Share Peak Sales Concerta Aug % $1.3 BB Adderall XR Oct % $1.1 BB Strattera Nov % $667 MM Focalin XR May % ~$400 MM Vyvanse Jun % $1.2 BB* Intuniv Nov % $335 MM * Sales are still growing 8
9 US Pricing for Major ADHD Brands shows a Price per Month range of $200-$300 Product WAC Avg Price/Rx 5 Year Price CAGR Concerta $ % Vyvanse $ % Intuniv $ % * Strattera $ % *4 year CAGR Source: IMS NPA, Wolters Kluwer Prices represent weighted average of all doses 9
10 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 10
11 Quantitative Research of Unmet Needs in ADHD Methodology Structured quantitative questionnaire Data collection via the Internet Fieldwork timing: April 2014 Sample size: 127 respondents recruited from target list High Prescribers recruited from list of top 5,000 ADHD prescribers in the US KOLs recruited from list of KOLs provided by Alcobra Specialty Number of Respondents PSYCHs 64 PCPs 31 Neuros 5 Total High Prescribers 100 KOLs 27 Total Respondents
12 Respondents indicate non-stimulants/medications w/low abuse potential are the greatest unmet need, followed by longer acting medications Unmet Needs Associated with Currently Available ADHD Treatments (Unaided) (Percent of Respondents) Non-stimulant / low abuse potential 42% Long-acting 36% Cost / coverage 20% Minimal side effects 17% Once-a-day dosing 13% Efficacy 6% Increased education 4% n = 127 A0. Doctor, in your opinion, what are the greatest unmet needs surrounding currently available ADHD treatments? 12
13 90% of respondents agree that there is an unmet need for a safe and effective non-addictive ADHD drug for adults; 80% agree that there is an unmet need for fast acting non-stimulant medications Agreement with Statements Regarding the Treatment with ADHD - Total Respondents Percent of Respondents Agreeing (High Rating: 5-7) Mean Rating It is very important to develop a safe and effective non-addictive ADHD drug for adults 90% 6.1 There is an unmet need for a fast acting non-stimulant ADHD medication 83% 5.7 The utility of stimulants for ADHD is hindered by the potential risk of abuse 70% 5.0 I have some adult ADHD patients that don't take medication because they don't want to take a stimulant 66% 4.9 n = 127 B1. Below is a list of statements regarding the treatment of ADHD. Please indicate the extent to which you agree with each of the following statements. 13
14 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 14
15 MDX Product Profile Market Research Methodology Implementation of the project was via web-assisted telephone interviews (WTIDIs) A total of n=16 interviews were conducted among the target audience Psychs n=7 PCPs n=9 Interviews lasted approximately 60 minutes each All respondents were recruited from the client supplied list and Were board-certified or board-eligible In full-time practice, spent at least 75% of time in clinical practice and had been practicing for at least 2 years, but no more than 35 years Were treating at least 100 patients with ADHD per month and at least 70 of these patients were Adults (18 years of age or older) Currently treating at least 30% of their Adult ADHD patients with pharmacotherapy 15
16 MDs are interested in MDX and rated themselves very likely to consider MDX for their Adult ADHD patients, particularly ADHD-PI patients A sub-set of MDs were then asked to rate their likelihood to consider use of MDX for various patient types. Most indicate that MDX would be used primarily as a 1 st line agent, replacing stimulants. Interest in Using MDX Patient Types Average Score* Overall Adult ADHD Patients 8.1 Predominantly inattentive type 9.0 Patients with history (not active) of substance abuse 8.0 Patients with two or more cardiovascular risk factors, e.g., smoking and overweight, overweight and hypertension, etc. 8.1 Patients who don t want to take a scheduled drug 9.4 Patients who have taken ADHD medications in the past (NOT currently taking ADHD medications) 8.3 *1=not at all to 10=extremely 16
17 MDs report interest in using MDX for 35%+ of their Adult ADHD patients Candidates for MDX Patient Types % of Adult ADHD Patients % Candidates for MDX Overall Adult ADHD Patients 100% 36% Predominantly inattentive type 52% 44% Patients with history (not active) of substance abuse 25% 53% Patients with two or more cardiovascular risk factors, e.g., smoking and overweight, overweight and hypertension, etc. 19% 70% Patients who don t want to take a scheduled drug 12% 90% Physicians also reported that almost 40% of their patients who have taken ADHD medications in the past, but are NOT currently taking ADHD medications would be candidates for MDX 17
18 MDX would draw patients from all existing therapies particularly Adderall XR and Strattera When asked how they might use MDX, about half of the physicians queried suggest they might consider using MDX in combination with a stimulant, to achieve greater efficacy Impact of MDX on Use of Agents Currently Prescribed Prescribed for Newly Diagnosed ADHD Patients % Respondents mentioning LESS USE of current agent with MDX available Strattera (atomoxetine) 69% Adderall XR/long acting (Branded or Generic amphetamine) 81% Vyvanse (lisdexamfetamine dimesylate) 50% Methylphenidate, short acting (Branded or Generic) 56% Concerta (methylphenidate) 38% Other long acting methylphenidate (Branded or Generic) 38% Intuniv (guanfacine) 19% 18
19 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 19
20 ADHD Pricing & Reimbursement Research Decision Resources conducted a series of 26 payer and KOL interviews to address key value proposition, pricing & market access, and product optimization dynamics. Respondents were recruited from national, regional, and local payer organizations. Stakeholder Groups Respondent Types Sample # of Lives Clinical KOLs P&T Advising Psychiatrists and Psychologists 4 N/A Commercial MCOs Medical Directors 7 Pharmacy Directors million Managed Medicaid MCOs Medical Directors 1 Pharmacy Directors million PBMs Pharmacy Directors million Total: 26 20
21 MCOs report limited attention to the ADHD category given the low to moderate budget impact Limited attention due to recent availability of generic versions of major brands (Adderall XR, Concerta) which offsets branded product costs MCOs are much more concerned about costs of specialty pharma products, e.g., Hepatitis C, and more populous conditions w/greater overall medical costs, e.g., Diabetes, Asthma Majority of respondents identify a reasonable price point for MDX between a premium to Vyvanse and a premium to Strattera price and report the likelihood of minimal management 21
22 Current ADHD Market Environment: Unmet Needs Respondents rate therapies with reduced potential for abuse, risk of addiction, and non scheduled agents as the three highest unmet medical needs Quality of Life data Dosing schedule Efficacy Onset of effect length of time for drug effect Effect on cognitive/executive function Risk of addiction Potential for abuse Non-scheduled Sexual side effects GI effects Effect on personality, creativity, mood lability Somnolence/sedation Effect on sleep (insomnia) Appetite suppression Effect on cardiovascular parameters Average Unmet Needs Total Payers and PBMs Average Rating Question: On a scale of 1 to 7 (1=low level of unmet need, 7= high level), how would you assess the level of unmet need for the following factors associated with existing drug therapies for ADHD? 22
23 Unmet Needs Evaluation of Product Z (MDX) for ADHD Level of Performance in Meeting Unmet Needs Respondents rate MDX the highest for its potential ability to reduce abuse, lower risk of addiction, and filling the unmet need for an unscheduled product option Level of Performance in Meeting Unmet Needs MDX Improved Quality of Life data 4.17 Convenient dosing schedule 4.77 Improved efficacy 3.66 Improved onset of effect 3.95 Effect on cognitive/executive function Reduced risk of addiction Reduced potential for abuse Non-scheduled Fewer sexual side effects Less GI upset Fewer negative effects on personality, etc. Improved somnolence/sedation Improved effect on sleep (insomnia) Less appetite suppression Improvement of cardiovascular parameters Rated Level of Performance Question: How would you assess the level of performance of Product Z, in meeting unmet needs, on a scale of 1 to 7 (1=lowest performance, 7= high level of performance)? 23
24 Agenda The ADHD Market Unmet Needs Physician Reaction to MDX Managed Care Reaction to MDX Data-driven Forecast of MDX Sales 24
25 Data Driven Forecast: Current Situation & Assumptions Parameter Current Environment Forecast Assumption Baseline TRxs TRx Growth Rate Intended Share Years to Peak Share Baseline Price Annual Price Increase Gross-Net Ratio 60 million (IMS NPA) 8.5% (5 year CAGR) 36% (from Mkt Res) 2-6 years (IMS NPA) $210/mo (Vyvanse) - $295/mo (Strattera) 11-15% (5 year CAGR) N/A 60 million 5% 9% 6 years $243/mo 5% 70% 25
26 Data Driven Forecast: Derivation of MDX Forecast* ADHD Market TRx 60 million 93 million x MDX TRx Share 9% x Price/Month $243 $377 Gross Sales $3.2 billion x Gross-Net Ratio 70% Net Sales Sensitivity Analysis +/- 1% Market Growth +/- $200 MM +/- 1% TRx Share +/- $250 MM +/- 1% Annual Price Increase +/- $200 MM +/- 1% Gross-Net Ratio +/- $30 MM *Assumes 2017 launch $2.2 billion
27 Summary and Conclusions ADHD Market is large and growing, especially Adults Despite the success of ADHD brands, substantial unmet need remains according to MDs MDs react very favorably to the product profile for MDX MCOs are not aggressively managing ADHD category and react favorably to MDX, as well >$8 billion in annual sales in the US Adult ADHD is now about half of all Rxs and growing at annual rate of ~10% Unscheduled, non-abusable drugs identified as greatest need Fast-acting, non-stimulant medications are highly desirable MDs indicate interest in MDX for 36% of Adult ADHD patients Even more favorable in key patient segments, e.g., PI-ADHD, History of substance abuse, Tolerability problems with simulants High receptivity to using MDX in diagnosed Adults with ADHD who are not currently taking Rx medications ADHD is not a high concern category for most MCOs MDX addresses unmet needs that MCOs identify Plans expect to manage MDX loosely through co-pays Projected Sales > $2 billion by
28 THANK YOU
Alcobra Ltd. (NASDAQ:ADHD) June Dr. Yaron Daniely President & CEO
Alcobra Ltd. (NASDAQ:ADHD) June 2015 Dr. Yaron Daniely President & CEO 1 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some
More informationAlcobra Ltd. (NASDAQ:ADHD) June 2016
Alcobra Ltd. (NASDAQ:ADHD) June 2016 1 1 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking statements
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationInvestors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD
Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD February 7, 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationConsolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults
FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationCowen Healthcare Conference Shire plc
Cowen Healthcare Conference Shire plc Michael Cola President, Specialty Pharmaceuticals THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationABOUT ADHD IN PRESCHOOL CHILDREN
Press Release www.shire.com Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD Lexington,
More informationAlcobra Ltd. Nasdaq:ADHD Corporate Presentation
Alcobra Ltd. Nasdaq:ADHD Corporate Presentation March 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationLATUDA Commercial Update
LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc. Sunovion Is Uniquely Positioned to Deliver Strong Performance
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationPress Release
Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD - Potential Launch of SHP465 Anticipated in Second Half of 2017 - Exclusivity for Shire s Overall
More informationUnderstanding and Addressing Abuse of ADHD Stimulants. David Baker Chief Commercial Officer Alcobra Inc.
Understanding and Addressing Abuse of ADHD Stimulants David Baker Chief Commercial Officer Alcobra Inc. March 8, 2017 1 Disclosures I am a full-time employee of Alcobra Inc. Alcobra is a public, CNS specialty
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationConroe ADHD Solutions
Diagnosis and Medical Management of ADD/ADHD How do we make the diagnosis of ADD/ADHD? We are very careful to be sure we have the diagnosis correct before considering treatment. In the past there were
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationPositive response from European Decentralised Procedure for Elvanse Adult (lisdexamfetamine dimesylate) in adults with ADHD
Press Release w w w.shire.com For Release to US Media Only Positive response from European Decentralised Procedure for Elvanse Adult (lisdexamfetamine dimesylate) in adults with ADHD Lexington, Mass. January
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationHalf life of focalin xr
Cari untuk: Cari Cari Half life of focalin xr 24-12-2016 Find a comprehensive guide to possible side effects including common and rare side effects when taking Adderall XR (Amphetamine, Dextroamphetamine
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationTargeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationUnderstanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD
Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD Dr. Don Duncan Clinical Director BC Interior ADHD Clinic Kelowna, BC Mental Health Summit Vancouver, BC December
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationConversion from focalin xr to vyvanse
Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationWhat are the most common signs of ADHD? And what are the most common medication interventions?
What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina
More informationMorgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc
Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product
More informationA Rare Opportunity in Transplant.
A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationDUPIXENT FDA Approval Call March 28, 2017
DUPIXENT FDA Approval Call March 28, 2017 1 Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationShire plc. Matthew Emmens, CEO
Shire plc Matthew Emmens, CEO THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationREFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - Executive Summary The Table below presents the key metrics of Ironwood/Actavis/Almirall/Astellas Linzess for
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationBank of America Merrill Lynch Global Healthcare Conference 2012
Bank of America Merrill Lynch Global Healthcare Conference 2012 Shire plc September 12, 2012 Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationCowen Healthcare Conference March 12, 2018
Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationConsumer Care A Strong Foundation in Consumer Health
Consumer Care A Strong Foundation in Consumer Health Spring Investors Conference 2004 Leverkusen, March 19, 2004 Gary S. Balkema President Consumer Care Division Safe Harbor This presentation contains
More informationShire Pharmaceuticals Group plc
Third Quarter Results Period ending 30 September 2003 5 November 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationREFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationA REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationREFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Prometheus Lotronex for irritable bowel syndrome
More informationAttention Deficit Hyperactivity Disorder or ADHD
Diagnosis/Disease/Illness Si usted desea esta información en español, por favor pídasela a su enfermero o doctor. Name of Child: Date: Attention Deficit Hyperactivity Disorder or ADHD What it is: Children
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationREFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013
REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013 ACUTE ISCHEMIC STROKE - Executive Summary Acute Ischemic Stroke: Key Metrics in Six Major Pharmaceutical Markets 2012 Epidemiology Prevalent Cases
More informationPress Release
Press Release www.shire.com Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting Research explores data on treatments for psychiatric
More informationMerrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc
Merrill Lynch Global Healthcare Conference February 4, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 995 The statements
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More information